[go: up one dir, main page]

MX2019010249A - Particulas pm21 para mejorar el anidamiento de la medula osea de celulas nk. - Google Patents

Particulas pm21 para mejorar el anidamiento de la medula osea de celulas nk.

Info

Publication number
MX2019010249A
MX2019010249A MX2019010249A MX2019010249A MX2019010249A MX 2019010249 A MX2019010249 A MX 2019010249A MX 2019010249 A MX2019010249 A MX 2019010249A MX 2019010249 A MX2019010249 A MX 2019010249A MX 2019010249 A MX2019010249 A MX 2019010249A
Authority
MX
Mexico
Prior art keywords
cells
particles
bone marrow
improve bone
marrow homing
Prior art date
Application number
MX2019010249A
Other languages
English (en)
Inventor
Copik Alicja
Oyer Jeremiah
Chakravarti Nitin
Anthony Lee Dean
Original Assignee
Univ Central Florida Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Central Florida Res Found Inc filed Critical Univ Central Florida Res Found Inc
Publication of MX2019010249A publication Critical patent/MX2019010249A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a composiciones y métodos para dirigir las células NK a la médula ósea mediante el uso de partículas PM21.
MX2019010249A 2017-02-28 2018-02-28 Particulas pm21 para mejorar el anidamiento de la medula osea de celulas nk. MX2019010249A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762464747P 2017-02-28 2017-02-28
PCT/US2018/020187 WO2018160673A1 (en) 2017-02-28 2018-02-28 Pm21 particles to improve bone marrow homing of nk cells

Publications (1)

Publication Number Publication Date
MX2019010249A true MX2019010249A (es) 2019-12-16

Family

ID=63370224

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010249A MX2019010249A (es) 2017-02-28 2018-02-28 Particulas pm21 para mejorar el anidamiento de la medula osea de celulas nk.
MX2024008576A MX2024008576A (es) 2017-02-28 2019-08-28 Particulas pm21 para mejorar el anidamiento de la medula osea de celulas nk.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024008576A MX2024008576A (es) 2017-02-28 2019-08-28 Particulas pm21 para mejorar el anidamiento de la medula osea de celulas nk.

Country Status (12)

Country Link
US (2) US11696927B2 (es)
EP (1) EP3589296A4 (es)
JP (2) JP2020509021A (es)
KR (2) KR102811217B1 (es)
CN (1) CN110612108A (es)
AU (2) AU2018227801B2 (es)
BR (1) BR112019017942A2 (es)
CA (1) CA3057211A1 (es)
IL (2) IL309689A (es)
MX (2) MX2019010249A (es)
SG (1) SG11201907917XA (es)
WO (1) WO2018160673A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111918661A (zh) 2018-02-21 2020-11-10 得克萨斯大学体系董事会 用于活化和扩增自然杀伤细胞的方法及其用途
JP7683932B2 (ja) * 2019-01-24 2025-05-27 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド ナチュラルキラー細胞を刺激するための組成物及び方法
US20210077527A1 (en) * 2019-09-13 2021-03-18 The Research Institute At Nationwide Children's Hospital Universal donor selection method to identify nk-cell-donors
WO2021183776A1 (en) * 2020-03-11 2021-09-16 Research Institute At Nationwide Children's Hospital Nk cells and uses thereof for treatment of microbial infections
AU2021260997A1 (en) 2020-04-21 2022-12-22 Kiadis Pharma Intellectual Property B.V. Methods and system for validating flow cytometry measurements
WO2023086494A1 (en) * 2021-11-10 2023-05-19 Regents Of The University Of Minnesota Methods, compositions, and kits for expanding natural killer cells
JP2025534206A (ja) 2022-09-15 2025-10-15 アビディキュア アイピー ビー．ブイ． Ｎｋ細胞を刺激するための多重特異性抗原結合タンパク質及びその使用
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191137A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (es) 1968-10-17 1970-08-24
WO2005017115A2 (en) 2003-08-11 2005-02-24 Mount Sinai School Of Medicine Of New York University Cord blood-derived hematopoietic progenitor cells
DE602005020643D1 (de) * 2004-09-03 2010-05-27 Univ Chicago Verfahren zur aktivierung von nkt-zellen
US7998740B2 (en) * 2006-07-18 2011-08-16 Robert Sackstein Cytokine induction of selectin ligands on cells
AU2011279201B2 (en) * 2010-07-13 2016-01-21 Celularity Inc. Methods of generating natural killer cells
EP3567102A1 (en) 2012-04-24 2019-11-13 Dan S. Kaufman Method for developing natural killer cells from stem cells
EP3578201B1 (en) 2012-06-28 2023-04-19 University Of Central Florida Research Foundation Incorporated Methods and compositions for natural killer cells
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
RU2015108761A (ru) * 2012-08-13 2016-10-10 Антродженезис Корпорейшн Природные клетки-киллеры и их применение
SG11201610699XA (en) * 2014-07-07 2017-01-27 Targazyme Inc Manufacture and cryopreservation of fucosylated cells for therapeutic use
WO2016069607A1 (en) 2014-10-27 2016-05-06 University Of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells

Also Published As

Publication number Publication date
AU2024203371A1 (en) 2024-06-06
US20200061115A1 (en) 2020-02-27
IL268945B2 (en) 2024-05-01
JP2020509021A (ja) 2020-03-26
IL268945B1 (en) 2024-01-01
KR20240058970A (ko) 2024-05-07
CN110612108A (zh) 2019-12-24
BR112019017942A2 (pt) 2020-05-19
IL309689A (en) 2024-02-01
EP3589296A1 (en) 2020-01-08
RU2019129841A (ru) 2021-03-30
JP7784089B2 (ja) 2025-12-11
KR102811217B1 (ko) 2025-05-22
JP2023093484A (ja) 2023-07-04
RU2019129841A3 (es) 2021-07-06
EP3589296A4 (en) 2020-09-09
US11696927B2 (en) 2023-07-11
KR20190124268A (ko) 2019-11-04
WO2018160673A1 (en) 2018-09-07
SG11201907917XA (en) 2019-09-27
AU2018227801B2 (en) 2024-02-22
IL268945A (en) 2019-10-31
MX2024008576A (es) 2024-07-22
AU2018227801A1 (en) 2019-09-19
US20230293585A1 (en) 2023-09-21
KR102661091B1 (ko) 2024-04-26
CA3057211A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
MX2019010249A (es) Particulas pm21 para mejorar el anidamiento de la medula osea de celulas nk.
MX2024012899A (es) Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
EA202190974A1 (ru) Противовирусные пролекарства и их наносоставы
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
MX2018004475A (es) Agentes biologicos y su uso en plantas.
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
BR112018008877A8 (pt) inibidores de ret
MX375352B (es) Reguladores de nrf2.
BR112018017091A2 (pt) profármacos de pth
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
UY36287A (es) COMPUESTO DE OBJETIVO A IL-23A y TNF-ALFA Y USO DEL MISMO
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
AR106285A1 (es) Alelos de la almidón sintasa ii de semillas de cereales y sus usos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
MX2019007336A (es) Polimorfos.
BR112015025852A2 (pt) as formulações de oxabicicloheptanos e oxabicicloheptenos
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
MX2017015315A (es) Granos de gluten reducido y composiciones de los mismos.
CO2019013718A2 (es) Anticuerpos anti-trkb